May 12, 2008
New Study Demonstrates Actemra (tocilizumab) Inhibits Progression of...
“At one year, the results from the LITHE trial clearly demonstrate that ACTEMRA could be an effective component in the battle against the long-term debilitating effects of RA, including joint damage and loss of physical function”
Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis , a ... via Med Ad News
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

